Baltimore, MD, United States of America

SangKon Oh

This inventor holds 29 USPTO granted patents and 15 published patent applications and 10 EPO patents, primarily in Immunotherapy Research. Top assignee: Baylor Research Institute. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: SangKon Oh. Retrieved from https://idiyas.com/inventor/sangkon-oh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 

% Patents Active = 96.6

 

Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 178(Granted Patents)


Company Filing History:


Years Active: 2012-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Immunotherapy
HPV Vaccines
Dendritic Cells
Anti-CD40 Antibodies
Cancer Antigens
Autoimmune Treatments
Inflammatory Conditions
Fusion Proteins
Antigen-Presenting Cells
OX40L Antibodies
Allergy Control
HIV-1 Gag/Nef
29 patents (USPTO):Explore Patents

Title: Innovations and Contributions of SangKon Oh in Biomedical Patents

Introduction

SangKon Oh, based in Baltimore, MD, is a prominent inventor with an impressive portfolio of 28 patents. His groundbreaking work primarily focuses on innovative vaccines and treatments that target significant health concerns, such as human papillomavirus (HPV) and multiple sclerosis. Through his research, he aims to enhance therapeutic strategies and improve patient outcomes.

Latest Patents

One of SangKon Oh's most noteworthy patents is his work on vaccines against HPV and HPV-related diseases. These vaccines are designed to combat multiple types of cancers associated with HPV. The formulation includes anti-human dendritic cell surface receptor antibodies, specifically targeting CD40, along with E6/7 proteins derived from HPV16 and HPV18. This innovative technology is versatile, allowing for the development of vaccines against various strains of HPV by targeting dendritic cells and inducing strong immune responses, including potent CD4+ and CD8+ T cell activations. Furthermore, his research extends to developing dendritic cell ASGPR targeting immunotherapeutics for treating multiple sclerosis, focusing on methods that utilize anti-ASGPR antibodies fused with essential myelin proteins.

Career Highlights

SangKon's career has seen significant contributions while collaborating with renowned institutions such as the Baylor Research Institute. His work is instrumental in advancing the understanding and treatment options available for viral infections and autoimmune diseases. His extensive research and development efforts have placed him at the forefront of medical innovations.

Collaborations

Throughout his career, SangKon Oh has worked alongside notable colleagues, such as Gerard Zurawski and Sandra M. Zurawski. Their collaboration has fostered an environment of innovation, driving forward the research aimed at developing effective therapeutic solutions.

Conclusion

SangKon Oh's contributions to the field of biomedical patents exemplify the impact of innovation in healthcare. His latest patents reflect a commitment to addressing critical health challenges, paving the way for new preventive and therapeutic strategies. As an inventor, his work is shaping the future of immunotherapy and vaccine development, making significant strides towards better health outcomes for individuals affected by HPV and multiple sclerosis.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…